SAT-433 Long-Acting Pasireotide Provides Clinical Benefit to Patients with Uncontrolled Acromegaly over Continued Treatment with First‑Generation Somatostatin Analogues (SSAs): Results from Phase 3b, Open-Label Study

Background: In a 24-week, Phase 3 study (PAOLA), long-acting pasireotide demonstrated superior efficacy (GH <2.5 µg/L and IGF-1 <ULN) over continued treatment with long-acting octreotide/lanreotide in pts with uncontrolled acromegaly (Gadelha MR, et al. Lancet Diabetes Endocrinol. 2014;2:875-8...

Descripción completa

Detalles Bibliográficos
Autores principales: Gadelha, Mônica, Colao, Annamaria, Bex, Marie, Campigotto, Federico, Bartalotta, Amy, Maamari, Ricardo, Raverot, Gérald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Neuroendocrinology and Pituitary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552256/
http://dx.doi.org/10.1210/js.2019-SAT-433

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552256/
http://dx.doi.org/10.1210/js.2019-SAT-433

Ejemplares similares